Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMO | O15229 | 2/20 | 0.47 |
| ▸ | NOS3 | P29474 | 1/20 | 0.44 |
| ▸ | NOS2 | P35228 | 1/20 | 0.44 |
| ▸ | MPL | P40238 | 1/20 | 0.44 |
| ▸ | FEN1 | P39748 | 12/20 | 0.43 |
| ▸ | ALOX5AP | P20292 | 11/20 | 0.43 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.39 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.38 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.37 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29766830 | 1.00 | KMO (0.47) | KMONOS3NOS2MPLFEN1 | |
| SCHEMBL29766838 | 0.94 | KMO (0.43) | KMONOS3NOS2MPLFEN1 | |
| SCHEMBL1477167 | 0.85 | ALOX5AP (0.49) | KMOFEN1ALOX5APPDK1PDK2 | |
| SCHEMBL29463696 | 0.85 | ALOX5AP (0.49) | KMOFEN1ALOX5APPDK1PDK2 | |
| SCHEMBL29445848 | 0.82 | KMO (0.54) | KMO | |
| SCHEMBL19072696 | 0.82 | KMO (0.54) | KMO | |
| SCHEMBL28726696 | 0.81 | NPC1 (0.49) | NOS3NOS2MPLGPBAR1 | |
| SCHEMBL18003318 | 0.80 | FEN1 (0.44) | NOS3NOS2MPLFEN1ALOX5AP | |
| SCHEMBL810884 | 0.78 | NOS3 (0.61) | KMONOS3NOS2 | |
| SCHEMBL28726704 | 0.77 | NOS3 (0.48) | NOS3NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114891043-B | Preparation method of cationic iridium (III) complex | 昆明贵金属研究所 | 2024-04-26 | — | — | CN | claimed |
| CN-114891043-A | Preparation method of cationic iridium (III) complex | 昆明贵金属研究所 | 2022-08-12 | — | — | CN | claimed |
| EP-3187503-B1 | ORGANOIRIDIUM COMPLEX FOR ORGANIC ELECTROLUMINESCENT ELEMENT | TANAKA PRECIOUS METAL IND (JP) | 2019-03-27 | — | — | EP | disclosed |
| US-20170237021-A1 | ORGANIC IRIDIUM COMPLEX FOR ORGANIC ELECTROLUMINESCENT ELEMENTS | TANAKA KIKINZOKU KOGYO K.K. (JP) | 2017-08-17 | — | — | US | disclosed |
| EP-3187503-A1 | ORGANIC IRIDIUM COMPLEX FOR ORGANIC ELECTROLUMINESCENT ELEMENTS | Tanaka Kikinzoku Kogyo K.K. (JP) | 2017-07-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170237021-A1 | ORGANIC IRIDIUM COMPLEX FOR ORGANIC ELECTROLUMINESCENT ELEMENTS | L1CAM, ETFA, TTI2 | KMO 2882/4885NOS3 3019/4885NOS2 1659/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.